Harveer Dev
YOU?
Author Swipe
View article: Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair
Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair Open
Clinical trials show benefit of the combination of poly(ADP-ribose) polymerase inhibitors (PARPi) with androgen receptor (AR) pathway inhibitors (ARPi) in metastatic, castration-resistant prostate cancer. While benefit was evident in patie…
Silent Threats Behind Bars: Prevalence of Oral Potentially Malignant Disorders among Bangalore Prison Inmates Open
Background: Health is a human right, and every individual is therefore entitled to access health care in the same conditions throughout their life course. In the case of prisons, as elsewhere, this is of the utmost importance. Oral potenti…
View article: supplementary materials 1 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer
supplementary materials 1 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer Open
supplementary materials
View article: Figure S2 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer
Figure S2 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer Open
Additional RNA sequencing analysis performed from CANCAP03 study.
View article: Data from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer
Data from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer Open
Purpose:The purpose was to investigate combined PARP and androgen inhibition in primary prostate cancer and understand the biological mechanisms underlying clinical efficacy, especially in the absence of mutations in homologous recombinati…
View article: Figure S3 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer
Figure S3 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer Open
Single cell RNA Seq data
View article: Figure S1 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer
Figure S1 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer Open
Graph of % change in PARylated protein (PAR) expression against % change in PSA from baseline (pre-treatment) for olaparib and olaparib plus degarelix cohorts.
View article: Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer
Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer Open
Purpose: The purpose was to investigate combined PARP and androgen inhibition in primary prostate cancer and understand the biological mechanisms underlying clinical efficacy, especially in the absence of mutations in homologous recombinat…
Prostate cancer detection through unbiased capture of methylated cell-free DNA Open
Prostate cancer screening using prostate-specific antigen (PSA) has been shown to reduce mortality but with substantial overdiagnosis, leading to unnecessary biopsies. The identification of a highly specific biomarker using liquid biopsies…
53BP1 and double-strand break repair pathway choice in cancer Open
The cellular response to DNA double-strand breaks (DSB) is principally the result of two competing repair pathways. The Tumour Protein P53 Binding Protein 1 (TP53BP1) gene product plays a central role in DSB repair pathway choice, promotin…
Staphylococcus aureus urinary tract bacteriuria: single-institutional antibiotic susceptibility trends over a decade Open
Objectives: Methicillin resistant Staphylococcus aureus (MRSA) is a troublesome pathogen which is difficult for clinicians to treat. The purpose of this surveillance program is to assess the prevalence of MRSA urinary tract infections and …
LB-S&T-02 EXTENDED SPECTRUM BETA-LACTAMASE (ESBL) PRODUCING ENTEROBACTERIACEAE IN HOSPITAL URINARY TRACT INFECTIONS – INCIDENCE AND ANTIBIOTIC SUSCEPTIBILITY PROFILE Open
You have accessJournal of UrologyLate-Breaking S&T Poster1 Apr 2016LB-S&T-02 EXTENDED SPECTRUM BETA-LACTAMASE (ESBL) PRODUCING ENTEROBACTERIACEAE IN HOSPITAL URINARY TRACT INFECTIONS – INCIDENCE AND ANTIBIOTIC SUSCEPTIBILITY PROFILE Liam T…
Vancomycin resistant enterococci in urine cultures: Antibiotic susceptibility trends over a decade at a tertiary hospital in the United Kingdom Open
The incidence of vancomycin resistance among urinary isolates was stable over the last decade. Although resistance to nitrofurantoin has increased, it still serves as an appropriate first choice in uncomplicated urinary tract infection cau…